Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
ID: 354240Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354240

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and Alzheimer's Disease/AD-Related Dementias (ADRD)." This initiative invites applications that propose innovative strategies to target and manipulate specific brain cell subtypes associated with aging and ADRDs, utilizing advanced techniques such as adeno-associated virus (AAV) capsid engineering. The funding aims to support research that enhances understanding of neurodegeneration mechanisms, with a total funding availability of approximately $6 million over a maximum project duration of 5 years, divided into two phases: R61 for preliminary activities lasting up to 2 years and R33 for implementation and hypothesis testing lasting up to 3 years. Interested applicants must submit their proposals by October 7, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for further details at https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-25-024-Full-Announcement.html
    RFA-AG-25-024.html
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and Alzheimer's Disease/AD-Related Dementias (ADRD)." This initiative invites applications that propose innovative strategies to target and manipulate specific brain cell subtypes related to aging and ADRDs. The funding comprises two phases: the R61 phase allows up to 2 years for preliminary proof-of-principle activities, while the R33 phase permits an additional 3 years for implementation and hypothesis testing. Key research goals encompass optimizing targeted delivery using adeno-associated viruses (AAVs) and manipulating brain subtypes in animal models to explore underlying mechanisms of neurodegeneration. Priority will be given to novel approaches that leverage advances in technology and multi-omic data. Funding availability is approximately $6 million, with a maximum project duration of 5 years. Applications must comply with specified guidelines, and successful proposals will undergo peer review before consideration for funding. This bottom-up research effort aligns with the public health response to the growing incidence of Alzheimer's and related disorders, aiming to drive significant scientific advancements in understanding and addressing neurodegenerative diseases.
    Similar Opportunities
    Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development and validation of human cellular models for Alzheimer's Disease-Related Dementias (ADRD) through the R01 Research Project Grant mechanism. This initiative aims to create novel and complex cellular models that accurately reflect the multifaceted pathologies and various cell types associated with ADRD, with a strong emphasis on validation against human data to ensure scientific rigor. The total funding commitment for this opportunity is anticipated to be up to $4.5 million for FY2025, with individual project budgets capped at $500,000 in direct costs annually for a maximum duration of five years. Interested applicants can find more details and guidelines in the full announcement available at NIH Grants, and inquiries can be directed to grantsinfo@nih.gov. The application deadline is October 21, 2024.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)." This grant aims to support innovative research that elucidates the molecular mechanisms and functional implications of RNA modifications in relation to brain aging and Alzheimer's disease (AD) and related dementias (ADRD), including Lewy body dementia and frontotemporal dementia. The initiative is crucial for advancing understanding in this field, with the ultimate goal of identifying biomarkers and therapeutic targets that could lead to improved health outcomes for affected populations. Eligible applicants can request up to $500,000 in direct costs per year for projects lasting a maximum of five years, with a total funding allocation of $4 million for fiscal year 2025. Applications are due by November 1, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD," aimed at catalyzing innovative research into the molecular mechanisms of RNA modifications related to brain aging and Alzheimer's disease (AD) and related dementias. This initiative seeks exploratory and developmental grant applications (R21) that focus on identifying critical RNA modification sites, understanding their functional impacts, and exploring gene regulation mechanisms relevant to aging and AD, with an emphasis on open-science practices and data sharing through the Alzheimer's Disease Knowledge Portal. Up to $1.4 million is available for five anticipated awards, with individual project budgets capped at $275,000 over a two-year period. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Investigations into Alzheimer’s Disease-Related Dementias (ADRD) Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)." This grant aims to support research that investigates the interactions of multiple co-pathologies associated with ADRD, focusing on their cellular and molecular mechanisms and their impact on cognitive and functional impairments. The initiative is part of a broader commitment to advance neuroscience research and address public health challenges related to dementia, with particular emphasis on studies that explore co-pathologies such as tau and alpha-synuclein. Interested applicants can apply for funding up to $500,000, with applications due by October 4, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html.
    Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Functional Target Validation for Alzheimer’s Disease-Related Dementias (ADRD) through a phased R61/R33 grant program. This initiative aims to support the comprehensive functional validation of therapeutic target candidates identified via genetic or tissue analysis in human samples, with a focus on developing technologies and models to assess their effects. The program is critical in addressing the urgent need for novel therapeutic strategies for ADRD, which includes disorders such as frontotemporal degeneration and vascular contributions to cognitive impairment. Interested applicants, including academic institutions and community-based organizations, must submit their proposals by November 8, 2024, and can find further details at the NIH grants website or contact grantsinfo@nih.gov for inquiries.
    Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD)" through a U01 cooperative agreement mechanism. This initiative aims to support the optimization of promising genome editing-based therapeutic leads for ADRD, focusing on preparing these candidates for Investigational New Drug (IND)-enabling studies. The funding is crucial for advancing research in various forms of ADRD, including Frontotemporal Dementia and Lewy Body Dementia, by refining therapeutic candidates to ensure their safety and efficacy. Interested applicants can apply for up to $1 million in funding, with a total budget commitment of up to $3 million per year for two awards, and must submit their applications by November 19, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)" aimed at investigating the interactions between COVID-19 and Alzheimer’s Disease-Related Dementias (ADRD). This initiative seeks research proposals that utilize animal, cell culture, or human tissue models to explore the mechanisms by which COVID-19 affects CNS pathology and cognitive outcomes, particularly in the context of existing AD/ADRD conditions. The NIH plans to allocate up to $3.75 million to support up to five awards, with individual budgets capped at $500,000 in direct costs per year. Interested applicants must submit their proposals by October 4, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment," aimed at investigating the impact of environmental risk factors (ERFs) on Alzheimer's Disease-Related Dementia (ADRD). This initiative seeks to explore how exogenous ERFs, such as toxins and pathogens, influence ADRD mechanisms at innervated human surfaces, including the gut, lungs, and skin, while explicitly prohibiting clinical trials. The NIH plans to allocate up to $3.75 million annually for this initiative, with individual project budgets capped at $500,000 over a maximum duration of five years. Applications are due by October 6, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings," aimed at enhancing the understanding of Alzheimer’s Disease Related Dementias (ADRD). This initiative focuses on utilizing structural biology methodologies to investigate the relationships between protein structures and clinical outcomes of ADRD, specifically seeking to generate structural information on proteins implicated in the disease within their native cellular environments. The NIH plans to allocate up to $3 million annually for up to four grants, with each grant not exceeding $500,000 per year for a maximum of five years, contingent upon funding availability. Interested applicants can submit their proposals starting September 4, 2024, with a submission deadline of October 5, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.